A Clomipramine Challenge Linked Withdrawal-Like Behavior and Histamine Changes in THC-Tolerant Rats

A 1985 rat experiment reported withdrawal-like behavior and regional histamine decreases after clomipramine challenge in THC-tolerant animals. The design was a pharmacological challenge, not simply observation after THC cessation.

Tolerance was established before the challenge

Repeated intravenous THC produced tolerance to cooling and to the acute regional histamine reductions over five days. Histamine concentration in brain tissue was the biochemical endpoint; it was not a direct measure of release or every function of the histamine system.

The intervention produced a linked pattern

Clomipramine administration to tolerant rats elicited a withdrawal-like behavioral syndrome alongside histamine decreases in several regions. THC given before the challenge attenuated both findings, while vehicle did not. The parallel changes support an interaction but do not prove that histamine depletion alone caused the behavior.

The challenge is not ordinary clinical use

A drug-provoked animal response does not establish what happens in every person taking clomipramine or stopping cannabis. The abstract does not isolate a single receptor mechanism or demonstrate a treatment for dependence. The description withdrawal-like should remain qualified.

The study offers historical evidence connecting cannabinoid adaptation, a pharmacological probe and regional neurochemistry. It does not support using THC to manage medication effects or altering prescribed treatment. Species, challenge drug and measured tissue changes define the limits of the observation.

Related: interpreting cannabis tolerance claims.

Research cited

Verberne AJ; Fennessy MR; Lewis SJ; Taylor DA. Involvement of brain histamine in delta 9-tetrahydrocannabinol tolerance and withdrawal. Pharmacology, biochemistry, and behavior (1985). doi:10.1016/0091-3057(85)90549-0. Findings discussed from the study abstract.